ReviewArthritis research & therapy2009
Randomized controlled trial design in rheumatoid arthritis: the past decade.
Review in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies.Clinical drug investigation · 2020Pooled it
- Placebo Response in Rheumatoid Arthritis Clinical Trials.The Journal of rheumatology · 2020Pooled it
- Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.Annals of the rheumatic diseases · 2011Pooled it
- Review
- Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases.Archives of pharmacal research · 2021Review
- Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis.Frontiers in immunology · 2021Review
- Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis.Journal of inflammation research · 2021Review
- Minimizing efficacy differences between phase II and III RCTs.Nature reviews. Rheumatology · 2020Article
- Pharmacological Inhibitors of the NLRP3 Inflammasome.Frontiers in immunology · 2019Review
- The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.Clinical and experimental immunology · 2018Article
- Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials.Rheumatology advances in practice · 2018Article
- Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.Clinical rheumatology · 2017Observational
- Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.Journal of managed care & specialty pharmacy · 2015Article
- Article
- A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.Results in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Much progress has occurred over the past decade in rheumatoid arthritis trial design. Recognized challenges have led to the establishment of a clear regulatory pathway to demonstrate efficacy of a new therapeutic. The use of pure placebo beyond 12 to 16 weeks has been demonstrated to be unethical and thus background therapy and/or early rescue has become regular practice. Goals of remission and 'treating to targets' may prove more relevant to identify real-world use of new and existing therapeutics. Identification of rare adverse events associated with new therapies has resulted in intensive safety evaluation during randomized controlled trials and emphasis on postmarketing surveillance and use of registries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.